---
title: "keynote-240"
date: "2024-06-20"
tags:
  - building
---

> ðŸŒ± created from: [[subsequent_therapies-of-hepatocellular_carcinoma]]

# keynote-240

- Design: Phase III, multi-center, randomized, double-blind
- Number of patients: 413
- Patients characteristics: Advanced HCC, previously treated with sorafenib
- Agent: Pembrolizumab plus best supportive care vs. placebo plus BSC
- Treatment line: Previously treated with sorafenib
- Trial Acronym (if provided) or NCTId Number: NCT02702401
- Comparison of efficacy in one markdown table
- Highlight of toxicity:
  - Grade 3 or higher adverse events occurred in 52.7% of pembrolizumab patients vs. 46.3% of placebo patients,
  - with treatment-related adverse events in 18.6% vs. 7.5%, respectively
- One line summarize:
- Pembrolizumab showed improved overall survival and progression-free survival in previously treated advanced HCC patients, with manageable adverse events.
